Militia Capital Partners LP Makes New Investment in PROCEPT BioRobotics Corporation $PRCT

Key Points

• Militia Capital Partners LP acquired 14,000 shares of PROCEPT BioRobotics, valued at approximately $816,000, highlighting institutional interest in the company.
• PROCEPT BioRobotics shares have seen a positive trend with a 48.3% increase in revenue year-over-year, although the company continues to report negative earnings per share (EPS).
• Research analysts have mixed views on PROCEPT, with price targets ranging from $58.00 to $73.22, indicating a consensus rating of "Moderate Buy" for the stock.

Militia Capital Partners LP bought a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,000 shares of the company's stock, valued at approximately $816,000.

Several other large investors have also modified their holdings of the stock. ANTIPODES PARTNERS Ltd acquired a new position in PROCEPT BioRobotics in the 1st quarter valued at approximately $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of PROCEPT BioRobotics during the first quarter worth $40,000. CWM LLC lifted its position in shares of PROCEPT BioRobotics by 69.5% in the first quarter. CWM LLC now owns 873 shares of the company's stock worth $51,000 after purchasing an additional 358 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in PROCEPT BioRobotics by 32.5% in the first quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company's stock valued at $64,000 after buying an additional 270 shares during the period. Finally, IFP Advisors Inc boosted its position in shares of PROCEPT BioRobotics by 358.9% in the first quarter. IFP Advisors Inc now owns 3,313 shares of the company's stock valued at $193,000 after acquiring an additional 2,591 shares during the period. Institutional investors own 89.46% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on PRCT shares. Stephens assumed coverage on PROCEPT BioRobotics in a research note on Wednesday, July 9th. They issued an "overweight" rating and a $70.00 price target on the stock. BTIG Research reiterated a "neutral" rating on shares of PROCEPT BioRobotics in a research report on Tuesday. Wall Street Zen upgraded PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Piper Sandler dropped their price objective on shares of PROCEPT BioRobotics from $80.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Finally, Oppenheimer upgraded shares of PROCEPT BioRobotics from a "market perform" rating to an "outperform" rating and set a $60.00 target price for the company in a research report on Tuesday, September 2nd. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of "Moderate Buy" and a consensus target price of $70.00.

PROCEPT BioRobotics Stock Up 4.1%

NASDAQ PRCT traded up $1.57 during trading on Tuesday, hitting $39.57. 1,430,956 shares of the company traded hands, compared to its average volume of 1,019,206. PROCEPT BioRobotics Corporation has a 12 month low of $36.90 and a 12 month high of $103.81. The company has a market capitalization of $2.20 billion, a P/E ratio of -25.53 and a beta of 1.03. The company has a current ratio of 9.21, a quick ratio of 7.86 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $46.39 and a 200 day simple moving average of $53.44.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.06. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. The business had revenue of $79.18 million during the quarter, compared to analysts' expectations of $75.67 million. During the same quarter in the prior year, the company earned ($0.50) EPS. The firm's quarterly revenue was up 48.3% on a year-over-year basis. As a group, sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).